Report
MSK for HBR: U.S. Medical Centers Need a New Model for Drug Discovery and Development
Overview
This Harvard Business Review article is primarily authored by leaders from Memorial Sloan Kettering Cancer Center (MSK), the New York–based cancer research and treatment institution. Four of the six authors are MSK leaders: Dr. Selwyn M. Vickers (President and CEO of MSK), Dr. Anaeze C. Offodile II (Executive Vice President and Chief Strategy Officer), Yashodhara Dash (Vice President of Entrepreneurship and Commercialization), and Dr. Whitney Snider (Managing Partner of MSK Ventures). They are joined by collaborators from Massachusetts General Hospital and Stanford. The authors explicitly disclose MSK’s central role in the research, and MSK’s institutional strategies are positioned as foundational case studies within the piece.
In This Article
Drawing heavily on its New York–based home institution, MSK anchors several of the article’s recommended solutions. As a strategic-partnership exemplar, MSK has formed alliances with more than ten AI-driven drug-development companies, embedding frontier algorithms across each phase of drug testing. The authors highlight MSK’s use of the AWS Drug Discovery Workbench to screen large compound libraries and run thousands of drug-binding simulations, alongside tools from Triomics that match cancer patients to clinical trials in real time. Another New York example cited is the Icahn School of Medicine at Mount Sinai, which recently launched an AI Small Molecule Drug Discovery Center that fuses generative AI with traditional medicinal chemistry to accelerate new drug design. On the global-collaboration front, the article points to MSK’s membership in the U.S.–Australia Alliance for Cancer Research and Treatment, a multi-stakeholder public-private partnership focused on first-in-human and Phase 1 trials, as a model for boosting patient enrollment, reducing duplicative testing, and harmonizing regulation across borders.
The Big Picture
MSK and Mount Sinai’s Icahn School of Medicine are presented as leading-edge proof points for the article’s five-part blueprint: embracing industry-style drug-development infrastructure, integrating AI and robotic automation, forming strategic AI partnerships, extending AMC investment into later-stage development, and driving global collaborations.
